Dr. Marina E. Manvelyan, MD

Dr. Manvelyan practices at Washington Medical Group in Pasadena, California.

Dr. Manvelyan's NPI, 1215925409, was assigned on October 11, 2005. Dr. Manvelyan graduated from Yerevan State Medical University in 1985. Dr. Manvelyan's California license number on file is A055018.

Dr. Manvelyan's primary practice is Washington Medical Group, at 2544 E Washington Blvd, Pasadena, CA 91107 in Los Angeles County. The practice phone is (626) 398-4069.

Dr. Manvelyan's primary practice is Washington Medical Group in Pasadena, California. Dr. Manvelyan is also affiliated with Huntington Hospital. The medical group on file is Washington Healthcare Center. Dmand AI also links Dr. Manvelyan to 1 more hospital, 3 home health agencies, 3 skilled nursing facilities, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Manvelyan practices, 10 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Manvelyan's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Manvelyan is board certified in internal medicine by the American Board of Internal Medicine. Dr. Manvelyan has a license on file in California.

Dmand AI lists acid reflux, acute gastroduodenitis, acute kidney failure, acute mini-stroke (TIA), acute sinusitis, acute skin infection, alzheimer's disease and aneurysm among the conditions Dr. Manvelyan treats.

CMS data shows 1,663 Medicare services from Dr. Manvelyan across 17 procedure codes in 2024, for 360 Medicare patients. Medicare paid $149,474 for them. Every service was in an office.

CMS counts 360 Medicare patients who saw Dr. Manvelyan in 2024. The largest group is 75 to 84, with 147 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Manvelyan's median patient age at 70, with 69% women.

In 2024, Dr. Manvelyan wrote 19,470 Medicare Part D claims for 713 patients. 83% of them were for generic drugs. CMS names the drug for 18,671 of them, across 262 drugs with 11 or more claims each, at $1,901,943 in total drug cost. In 2023, CMS named 18,137 claims across 238 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Manvelyan for performance year 2024, reported individually. Dr. Manvelyan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Manvelyan as offering telehealth.

Dmand AI links 14 papers to Dr. Manvelyan, published from 2008 to 2013. 2011 was the busiest year, with 4. The most frequent topics are Chromosome Aberrations, Karyotyping and Chromosomes, Human, Pair 14. Dr. Manvelyan has published most often in Mol Cytogenet.

CMS Open Payments shows 495 general payments to Dr. Manvelyan from 54 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $882.

Dr. Manvelyan graduated from Yerevan State Medical University in 1985.

Dr. Manvelyan is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.